Catalyst Pharmaceuticals, Inc.

Clinical trials sponsored by Catalyst Pharmaceuticals, Inc., explained in plain language.

Catalyst Pharmaceuticals, Inc. CPRX NASDAQ

A commercial-stage biopharma focused on rare neuromuscular and neurological diseases.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.

Trials to join now! 1

New study tracks long-term safety of DMD drug vamorolone in boys

Disease control Recruiting now

This study follows 250 boys (ages 2 and older) with Duchenne muscular dystrophy who are taking vamorolone (AGAMREE). Researchers will monitor side effects, growth, bone health, heart function, and quality of life over time. The goal is to better understand the long-term safety an…

Sponsor: Catalyst Pharmaceuticals, Inc. • Aim: Disease control

Last updated Jul 22, 2026 00:00 UTC

Catalyst Pharmaceuticals, Inc.

New study tracks long-term safety of DMD drug vamorolone in boys